Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target: Laboratory investigation

Wesley Hsu, Ahmed Mohyeldin, Sagar R. Shah, Colette M. Ap Rhys, Lakesha F. Johnson, Neda I. Sedora-Roman, Thomas A. Kosztowski, Ola A. Awad, Edward F. McCarthy, David M. Loeb, Jean Paul Wolinsky, Ziya L. Gokaslan, Alfredo Quiñones-Hinojosa

Research output: Contribution to journalArticlepeer-review

89 Scopus citations


Object. Chordoma is a malignant bone neoplasm hypothesized to arise from notochordal remnants along the length of the neuraxis. Recent genomic investigation of chordomas has identified T (Brachyury) gene duplication as a major susceptibility mutation in familial chordomas. Brachyury plays a vital role during embryonic development of the notochord and has recently been shown to regulate epithelial-to-mesenchymal transition in epithelial-derived cancers. However, current understanding of the role of this transcription factor in chordoma is limited due to the lack of availability of a fully characterized chordoma cell line expressing Brachyury. Thus, the objective of this study was to establish the first fully characterized primary chordoma cell line expressing gain of the T gene locus that readily recapitulates the original parental tumor phenotype in vitro and in vivo. Methods. Using an intraoperatively obtained tumor sample from a 61-year-old woman with primary sacral chordoma, a chordoma cell line (JHC7, or Johns Hopkins Chordoma Line 7) was established. Molecular characterization of the primary tumor and cell line was conducted using standard immunostaining and Western blotting. Chromosomal aberrations and genomic amplification of the T gene in this cell line were determined. Using this cell line, a xenograft model was established and the histopathological analysis of the tumor was performed. Silencing of Brachyury and changes in gene expression were assessed. Results. The authors report, for the first time, the successful establishment of a chordoma cell line (JHC7) from a patient with pathologically confirmed sacral chordoma. This cell line readily forms tumors in immunodeficient mice that recapitulate the parental tumor phenotype with conserved histological features consistent with the parental tumor. Furthermore, it is demonstrated for the first time that silencing of Brachyury using short hairpin RNA renders the morphology of chordoma cells to a more differentiated-like state and leads to complete growth arrest and senescence with an inability to be passaged serially in vitro. Conclusions. This report represents the first xenograft model of a sacral chordoma line described in the literature and the first cell line established with stable Brachyury expression. The authors propose that Brachyury is an attractive therapeutic target in chordoma and that JHC7 will serve as a clinically relevant model for the study of this disease.

Original languageEnglish (US)
Pages (from-to)760-769
Number of pages10
JournalJournal of neurosurgery
Issue number4
StatePublished - Oct 2011
Externally publishedYes


  • Animal model
  • Brachyury
  • Chordoma
  • Chordoma xenograft
  • JHC7 cell line
  • Oncology

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target: Laboratory investigation'. Together they form a unique fingerprint.

Cite this